Politics, Policy & Law
DiLenge predicts biopharma companies will ‘take a hit’ in infrastructure bill
BIO’s goal is to ensure that drug pricing legislation increases patient access, doesn’t harm innovation
BIO’s goal is to ensure that drug pricing legislation increases patient access without harming innovation.
As he prepares to leave BIO after 15 years, Tom DiLenge previewed the urgent policy challenges the industry will face in the coming months, including pending drug price control legislation that could reshape the U.S. market.
DiLenge, who has been BIO’s president for advocacy, law & public policy for the past five years after serving as